Israel Englander Forma Therapeutics Holdings, Inc. Transaction History

Millennium Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.12 - $20.24 $2.91 Million - $8.26 Million	-408,115 Reduced 93.87%	26,629 $531,000
Q2 2022 Aug 15, 2022	BUY	$5.1 - $10.0 $1.12 Million - $2.2 Million	219,603 Added 102.07%	434,744 $3 Million
Q1 2022 May 16, 2022	BUY	$8.34 - $14.69 $1.36 Million - $2.4 Million	163,365 Added 315.52%	215,141 $2 Million
Q4 2021 Feb 14, 2022	SELL	$13.6 - $24.89 $607,226 - $1.11 Million	-44,649 Reduced 46.3%	51,776 $736,000
Q3 2021 Nov 15, 2021	SELL	$21.22 - $25.7 $3,416 - $4,137	-161 Reduced 0.17%	96,425 $2.24 Million
Q2 2021 Aug 16, 2021	SELL	$22.86 - $30.95 $321,274 - $434,971	-14,054 Reduced 12.7%	96,586 $2.4 Million
Q1 2021 May 17, 2021	SELL	$24.58 - $42.82 $2.2 Million - $3.84 Million	-89,688 Reduced 44.77%	110,640 $3.1 Million
Q4 2020 Feb 16, 2021	BUY	$34.9 - $51.08 $6.99 Million - $10.2 Million	200,328 New	200,328 $6.99 Million
Q3 2020 Nov 16, 2020	SELL	$32.95 - $50.25 $10.4 Million - $15.8 Million	-315,006 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$39.0 - $46.49 $12.3 Million - $14.6 Million	315,006 New	315,006 $14.6 Million

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.